These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 16906667)

  • 1. Keeping up with drug safety information.
    Meadows M
    FDA Consum; 2006; 40(3):38-9. PubMed ID: 16906667
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharma's year of trouble and strife.
    Frantz S
    Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339
    [No Abstract]   [Full Text] [Related]  

  • 3. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulators equivocate on safety of clones.
    Powell K
    Nat Biotechnol; 2003 Dec; 21(12):1415-6. PubMed ID: 14647311
    [No Abstract]   [Full Text] [Related]  

  • 5. Advisory committees" critical to the FDA's product review process.
    Rados C
    FDA Consum; 2004; 38(1):17-9. PubMed ID: 15032199
    [No Abstract]   [Full Text] [Related]  

  • 6. Current and future state of FDA-CMS parallel reviews.
    Messner DA; Tunis SR
    Clin Pharmacol Ther; 2012 Mar; 91(3):383-5. PubMed ID: 22343814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LyphoMed sparks worries.
    Wagner M
    Mod Healthc; 1988 Jul; 18(29):5. PubMed ID: 10325202
    [No Abstract]   [Full Text] [Related]  

  • 8. Institute of Medicine's new drug safety report: implications for Canada.
    Cassels A
    CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
    [No Abstract]   [Full Text] [Related]  

  • 9. What's best for the patient?
    Burkle WS
    Am J Hosp Pharm; 1983 Apr; 40(4):558. PubMed ID: 6846359
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug advisory committees. Getting outside advice for close calls.
    Farley D
    FDA Consum; 1995 Mar; 29(2):23-6. PubMed ID: 10172354
    [No Abstract]   [Full Text] [Related]  

  • 11. Protecting the consumer from getting burned: the FDA, the administrative process, and the tentative final monograph on over-the-counter sunscreens.
    Jones PR
    Am J Law Med; 1994; 20(3):317-35. PubMed ID: 7702077
    [No Abstract]   [Full Text] [Related]  

  • 12. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 13. The issue of extralabel drug use.
    Kennedy JA
    J Am Vet Med Assoc; 1997 Dec; 211(11):1354. PubMed ID: 9394877
    [No Abstract]   [Full Text] [Related]  

  • 14. Vioxx, radiology, and the Food and Drug Administration.
    Pentecost MJ
    J Am Coll Radiol; 2005 May; 2(5):394-7. PubMed ID: 17411841
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulating drugs for effectiveness and safety: a public health perspective.
    Zito JM; Socolar SJ; Eilers R; Crystal S; Lexchin J
    Med Care; 2007 Sep; 45(9):911. PubMed ID: 17712264
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA embraces risk-management approach.
    Fox JL
    Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
    [No Abstract]   [Full Text] [Related]  

  • 17. Legal overprotection.
    Friedman JH
    Med Health R I; 2004 Oct; 87(10):294. PubMed ID: 15559378
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug product liability and health care delivery systems.
    Sage WM
    Stanford Law Rev; 1988 Apr; 40(4):989-1026. PubMed ID: 10318110
    [No Abstract]   [Full Text] [Related]  

  • 19. "Counter" intuitive.
    Weinberg JM
    Cutis; 2005 May; 75(5):261. PubMed ID: 15984624
    [No Abstract]   [Full Text] [Related]  

  • 20. Counterfeiting and piracy of pharmaceuticals.
    Grackin A
    IEEE Eng Med Biol Mag; 2008; 27(6):66-9. PubMed ID: 19004698
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.